MAGE-As 蛋白及mRNA在肺癌患者的表达水平变化及其临床意义

doi:10.3969/j.issn.1006-6233.2023.06.011

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1284 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨黑色素瘤相关抗原(MAGE)-As蛋白及mRNA在非小细胞肺癌中的表达及临床意义。方法: 选取2015年1月至2020年1月在我院治疗的非小细胞肺癌患者88例,同时选取癌旁组织作为对照,采用Western blot检测肺癌和癌旁组织MAGE-As蛋白表达,RT-PCR检测肺癌和癌旁组织MAGE-As mRNA表达。结果: 非小细胞肺癌组织MAGE-As蛋白及mRNA相对表达量分别为(0.343±0.101)和(0.728±0.112),明显高于癌旁组织(P<0.05);临床分期Ⅲ~Ⅳ期肺癌组织MAGE-As蛋白相对表达量为(0.385±0.102),明显高于Ⅰ~Ⅱ期肺癌组织(P<0.05);不同性别、年龄、肿瘤直径、病理类型、分化程度肺癌组织MAGE-As蛋白相对表达量比较差异无统计学意义(P>0.05);临床分期Ⅲ~Ⅳ期、中低分化程度肺癌组织MAGE-As mRNA相对表达量为(0.762±0.112)和(0.742±0.107),明显高于Ⅰ~Ⅱ期和高分化肺癌组织(P<0.05);不同性别、年龄、肿瘤直径、病理类型肺癌组织MAGE-As mRNA相对表达量比较差异无统计学意义(P>0.05);肺癌组织MAGE-As mRNA高表达和低表达患者中位总生存期为33个月和44个月,MAGE-As mRNA高表达和低表达患者生存率有所差异(P<0.05)。MAGE-As蛋白高表达和低表达患者中位总生存期差异比较无统计学意义(P>0.05)。结论: MAGE-As 蛋白及mRNA在非小细胞肺癌中表达上调,与病情严重程度有关,同时MAGE-As mRNA高表达患者预后较差。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：黑色素瘤相关抗原-As, 蛋白, mRNA, 非小细胞肺癌

Abstract：Objective: To investigate the expression and clinical significance of melanoma associated antigen (MAGE)-As protein and mRNA in non-small cell lung cancer. Methods: A total of 88 patients with non-small cell lung cancer treated in our hospital from January 2015 to January 2020 were selected, and the adjacent tissues were selected as the control, the expression of MAGE-As protein in lung cancer and adjacent tissues was detected by Western blot, and the expression of MAGE-As mRNA in lung cancer and adjacent tissues was detected by RT-PCR. Results: The relative expression levels of MAGE-As protein and mRNA in NSCLC tissues were (0.343 ± 0.101) and (0.728 ± 0.112), which were significantly higher than those in adjacent tissues (P<0.05); the relative expression of MAGE-As protein in stage Ⅲ ~Ⅳ lung cancer was (0.385 ± 0.102), which was significantly higher than that in stage Ⅰ~ Ⅱ lung cancer (P<0.05); there were no significant difference in the relative expression of MAGE-As protein in different gender, age, tumor diameter, pathological type and differentiation degree (P>0.05); the relative expression of MAGE-As mRNA in clinical stage Ⅲ~ Ⅳ and moderately and moderately differentiated lung cancer tissues were (0.762 ± 0.112) and (0.742 ± 0.107), which were significantly higher than those in stage Ⅰ~Ⅱ and well differentiated lung cancer tissues (P<0.05); there were no significant difference in the relative expression of MAGE-As mRNA in different gender, age, tumor diameter and pathological type (P>0.05). The median overall survival of patients with high and low MAGE-As mRNA expression in lung cancer tissues was 33 and 44 months, with a difference in survival between patients with high and low MAGE-As mRNA expression (P<0.05). The difference in median overall survival between patients with high and low MAGE-As protein expression was not statistically significant (P>0.05). Conclusion: The expression of MAGE as protein and mRNA are up-regulated in non-small cell lung cancer, is related to the severity of the disease, and the prognosis of patients with high expression of MAGE As mRNA is poor.

Key words： Melanoma associated antigen As Protein mRNA Non-small cell lung cancer

基金资助:广西自然科学基金项目,(编号:2022JJA140029)

引用本文:

李艳勇, 赵雪强, 陈家文, 杨革, 肖智宏. MAGE-As 蛋白及mRNA在肺癌患者的表达水平变化及其临床意义[J]. 河北医学, 2023, 29(6): 937-940.
LI Yanyong, ZHAO Xueqiang, CHEN Jiawen, et al. Changes in Expression Levels of MAGE-As Protein and mRNA in Lung Cancer Patients and Their Clinical Significance. HeBei Med, 2023, 29(6): 937-940.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2023.06.011 或 http://www.hbyxzzs.cn/CN/Y2023/V29/I6/937

[1] 谢忠海,沈琦斌,李冬,等.黑色素瘤抑制性活性蛋白在非小细胞肺癌中的表达及其对肿瘤生长及转移的作用研究[J].中国卫生检验杂志,2020,30(5):570-572,588.
[2] 何宗林,杜先智,邓嘉,等.黑色素瘤抗原A3 mRNA表达与NSCLC发生发展的关系[J].实用癌症杂志,2020,35(10):1612-1614.
[3] 张扬,邓明扬,李睿娟,等.以“黑骨髓”伴白血病样表型为首发表现的骨髓转移性黑色素瘤病例报道并文献复习[J].临床血液学杂志,2020,33(5):338-340,343.
[4] 李晓玲,黄仲,刘美莲.胸水细胞蜡块与"新鲜"胸水在肺腺癌EGFR基因检测中的应用[J].海南医学,2020,31(20):2668-2670.
[5] 王成吕,聂玉洁,潘润桑,等.三种新兴的免疫检查点分子在肿瘤免疫治疗中的研究进展[J].现代肿瘤医学,2022,30(7):1308-1312.
[6] 邹燕萍,章于潇,陈海欣,等.7项肿瘤相关自身抗体在早期非小细胞肺癌中的诊断价值[J].浙江医学,2021,43(18):1988-1991,1995,2051.
[7] Alexander M,Kim SY,Cheng H.Update 2020:management of non-small cell lung cancer[J].Lung,2020,198(6):897-907.
[8] Thai AA,Solomon BJ,Sequist LV,et al.Lung cancer[J].Lancet,2021,398(10299):535-554.
[9] 薛文姬,毕楠,杨琳,等.PD-L1在同步放化疗非EGFR突变局部晚期非小细胞肺癌中的表达及其与患者预后的关系[J].中华医学杂志,2022,102(6):406-411.
[10] Derosa L,Routy B,Thomas AM,et al.Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer[J].Nat Med,2022,28(2):315-324.
[11] Jasper K,Stiles B,McDonald F,et al.Practical management of oligometastatic non-small-cell lung cancer[J].Clin Oncol,2022,40(6):635-641.
[12] Hui Z,Men Y,Hu C,et al.Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy:the phase 3 PORT-C randomized clinical trial[J].JAMA Oncol,2021,7(8):1178-1185.
[13] Mithoowani H,Febbraro M.Non-small-cell lung cancer in 2022:a review for general practitioners in oncology[J].Curr Oncol,2022,29(3):1828-1839.
[14] Zhang JT,Liu SY,Gao W,et al.Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer[J].Cancer Discov,2022,12(7):1690-1701.